BusinessGalectin Therapeutics to Present at BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 8, 2017, 1:30 PM UTC
BusinessGalectin Therapeutics to Webcast Corporate Update At Annual Meeting of StockholdersBy Nasdaq OMXDec 8, 2016, 1:00 PM UTC
BusinessMats Wahlström Joins Surefire Medical Board of DirectorsBy Nasdaq OMXNov 30, 2016, 11:00 AM UTC
BusinessSurefire Medical Receives Grant to Pursue Phase 1b Clinical Trial of CAR-T Immunotherapy Delivery through Precision Infusion SystemBy Nasdaq OMXNov 15, 2016, 11:00 AM UTC
BusinessDaiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular CarcinomaBy Nasdaq OMXMar 22, 2016, 11:30 AM UTC
BusinessDendritic Cell Vaccine Inhibits Tumor Progression in Preclinical Liver Cancer ModelBy Nasdaq OMXFeb 25, 2016, 5:16 PM UTC
BusinessHuman Validation Data Supporting Saronic Biotechnology’s Lead Therapeutic SBI1997 Published in the Journal of ImmunotherapyBy Nasdaq OMXFeb 9, 2016, 4:11 PM UTC
BusinessArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 25, 2016, 12:31 PM UTC
